Results 21 to 30 of about 283,809 (263)
Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland
Swiss Medical Weekly, 2018 BACKGROUND The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete.
Jacqueline A. Bachofner +15 more
doaj +1 more source
Costs of Treatment, Follow-Up, and Complications of Chronic Hepatitis B and Hepatitis C Infections
Balkan Medical Journal, 2013 Background: Few studies have addressed the indirect costs of chronic hepatitis B and C, and none has assessed the real costs of these conditions, including indirect costs caused by loss of work, in Turkey. Aims: This study therefore analysed the costs of
Fatma Banu Karahasanoğlu +3 more
doaj +1 more source
Журнал инфектологии, 2014 Blood markers of endothelial activation (sVCAM-1, vWF: Ag) in patients with chronic hepatitis C in the presence of insulin resistance, metabolic syndrome and its components had been evaluated.
T. V. Antonova +2 more
doaj +1 more source
Hepatitis C prevalence in Denmark -an estimate based on multiple national registers
BMC Infectious Diseases, 2012 Background A national survey for chronic hepatitis C has not been performed in Denmark and the prevalence is unknown. Our aim was to estimate the prevalence of chronic hepatitis C from public registers and the proportion of these patients who received ...
Christensen Peer +8 more
doaj +1 more source
Therapeutic Apheresis and Dialysis, EarlyView.ABSTRACT Background Establishing a comprehensive apheresis medicine program in a resource‐constrained setting presents significant structural, financial, and logistical challenges. Despite the growing clinical importance of apheresis services globally, published experience from sub‐Saharan Africa remains sparse.
Folasade Adelekan‐Popoola +4 more
wiley +1 more source
Reciprocal control of viral infection and phosphoinositide dynamics
FEBS Letters, EarlyView.Phosphoinositides, although scarce, regulate key cellular processes, including membrane dynamics and signaling. Viruses exploit these lipids to support their entry, replication, assembly, and egress. The central role of phosphoinositides in infection highlights phosphoinositide metabolism as a promising antiviral target.
Marie Déborah Bancilhon, Bruno Mesmin
wiley +1 more source
The influence of hepatic steatosis on the success of antiviral therapy for chronic hepatitis C [PDF]
Vojnosanitetski Pregled, 2017 Background/Aim. Chronic hepatitis C and liver steatosis often appear simultaneously in the same person, and steatosis can lead to worsening of liver disease and reducing the success of the treatment of chronic hepatitis C.
Preveden Tomislav +2 more
doaj +1 more source
Phosphatidylinositol 4‐kinase as a target of pathogens—friend or foe?
FEBS Letters, EarlyView.This graphical summary illustrates the roles of phosphatidylinositol 4‐kinases (PI4Ks). PI4Ks regulate key cellular processes and can be hijacked by pathogens, such as viruses, bacteria and parasites, to support their intracellular replication. Their dual role as essential host enzymes and pathogen cofactors makes them promising drug targets.
Ana C. Mendes +3 more
wiley +1 more source
Case Reports in Gastroenterology, 2016 Following interferon-based therapy for chronic hepatitis C, the negativity of hepatitis C virus RNA is essential to achieve viral clearance at the end of treatment.
Akira Sato +5 more
doaj +1 more source
Molecular Oncology, EarlyView.LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source